← All trials
NCT06325748
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 22, 2024
- Primary completion
- Sep 30, 2025
- Completion date
- Aug 31, 2040
- First posted
- Mar 22, 2024
- Last posted
- Aug 6, 2024
- Enrollment
- 21
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Senti BiosciencesLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.